Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2004

View Archived Issues

KML-001 induces senescence, chromosomal instability in cancer cell lines with short telomerases

ARQ-501 induces antitumor effects in advanced cancer patients

Novel DPP-IV inhibitors under study at Guilford

GSK team prepares and tests new vanilloid VR1 antagonists for pain and other disorders

New beta2-adrenoceptor agonists covered by GSK patent

New glucocorticoid receptor agonists emerge from GSK R&D

Pfizer claims anti-c-Met antibodies and their use in cancer therapy

New research milestone in Pharmacopeia/Schering-Plough oncology collaboration

Antidiabetic thiazolidinediones prevent bone loss in a rat model of polyarthritis

Solifenacin decreases urgency in overactive bladder patients

Motexafin lutetium prevents atherosclerotic plaque increase after balloon angioplasty

Therapeutic benefits of sitaxsentan in PAH patients failing bosentan

Strontium ranelate reported to reduce fracture risk in very elderly osteoporotic women

Novel melanogenesis inhibitors developed at Takasago

New Hsp90 inhibitors and their use in cancer and other disorders

Women with polycystic ovary syndrome are at a greater risk for developing diabetes and heart disease

Preliminary analysis of phase III Prestara study shows primary endpoint not met

Orphan drug status for CoFactor for pancreatic cancer

Multiferon increases overall survival in melanoma study

CytRx acquires assets of Biorex Research & Development

RiboNovix develops antiinfectives less susceptible to drug resistance

SIGA-246 shows antiviral activity in mouse models of poxvirus disease

Merix Bioscience changes name to Argos Therapeutics, plans HIV study

Aplidin granted orphan drug status for multiple myeloma

Positive results from Lab International's phase I/II study of GHRH analogue

One-year treatment with ED-71 increases bone mineral density in osteoporotic patients

AMG-162 increases bone density of postmenopausal women with osteoporosis

Preclinical studies reveal anticancer potential of AZD-0530

AVE-5883 pharmacokinetics similar in healthy and asthmatic subjects

Studies assess fesoterodine myocardial safety, CYP interactions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...